Related Experiment Video
Updated: Oct 4, 2025
Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
Published on: April 19, 2024
Lianhua Qingwen Capsules Reduced the Rate of Severity in Patients with COVID-19: A System Review and Meta-Analysis of
Chengqian Shi1, Mizhi Wu2, Kepeng Yang1
1Department of Rheumatology, The Second Affiliated Hospital, Zhejiang Chinese Medical University, Hangzhou 310005, China.
Insights
Lianhua Qingwen (LQ) treatment significantly improved clinical efficacy and CT scans in mild to moderate COVID-19 patients. LQ also reduced the rate of developing severe coronavirus disease 2019 (COVID-19).
Area of Science:
- Infectious Diseases
- Clinical Medicine
- Pharmacology
Background:
- The severity rate of coronavirus disease 2019 (COVID-19) critically impacts patient prognosis and mortality.
- Lianhua Qingwen (LQ) is a Chinese patent medicine recommended for COVID-19 treatment.
- This meta-analysis investigates the effect of LQ on the severity rate in mild to moderate COVID-19 cases.
Purpose of the Study:
- To evaluate the association between Lianhua Qingwen (LQ) treatment and the severity rate in patients with mild or moderate COVID-19.
- To determine if LQ improves clinical efficacy and CT scan results in COVID-19 patients.
- To assess LQ's role in preventing the progression to severe COVID-19.
Main Methods:
- Systematic search of 7 electronic databases for randomized controlled trials (RCTs) up to March 27, 2021.
- Independent data extraction and quality assessment by two reviewers.
- Meta-analysis conducted using RevMan 5.3 software.
Main Results:
- Five RCTs involving 830 patients with mild or moderate COVID-19 were included.
- LQ treatment showed a significant association with higher clinical efficacy (RR=1.24) and CT improvement (RR=1.22) compared to conventional therapy.
- LQ treatment was associated with a significantly lower rate of conversion to severe cases (RR=0.47).
Conclusions:
- Lianhua Qingwen (LQ) combined with conventional therapy demonstrates significant benefits in reducing the severity rate of COVID-19.
- Findings support the routine use of LQ in managing mild to moderate COVID-19 cases.
- LQ shows potential in improving clinical outcomes and preventing disease progression in COVID-19 patients.
Background:
The rate of severity is a critical factor affecting the prognosis and mortality in coronavirus disease 2019 (COVID-19). Lianhua Qingwen capsules or granules (LQ) have been a promising Chinese patent medicine in treating infectious diseases and recommended for treating COVID-19. This meta-analysis aims to demonstrate the association between LQ treatment and the rate of severity in patients with mild or moderate COVID-19.
Methods:
7 electronic databases were systematically searched from the inception dates to March 27, 2021, using the search terms to identify randomized controlled trials (RCTs). Two reviewers independently identified studies, extracted the data, and assessed study quality. All analyses were conducted on RevMan 5.3 software.
Results:
A total of 5 RCTs involving 830 patients with mild or moderate COVID-19 were identified according to the inclusion and exclusion criteria. The quality of included studies is moderate. Compared with conventional therapy, there was a significant association of LQ treatment with a higher clinical efficacy (RR = 1.24, 95% CI (1.13, 1.36), P < 0.00001), rate of CT improvement (RR = 1.22, 95% CI (1.10, 1.34), P=0.0001), and a lower rate of conversion to severe cases (RR = 0.47, 95%CI (0.31, 0.71), P=0.0003).
Conclusion:
LQ combined with conventional therapy had great effects in reducing the rate of severity, and these findings supported the routine treatment of LQ in patients with mild or moderate COVID-19.
More Related Videos
04:34Meta-Analysis of the Effectiveness and Safety of Shugan Jieyu Capsules for the Treatment of Insomnia
Published on: February 17, 2023
08:15Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
Published on: June 6, 2025